Mangoceuticals MGRX Ratios (2022-2026)

NASDAQ MGRX
$0.41 +0.02 (+5.13%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Mangoceuticals Quarterly Ratios

Periods 15 quarters
Latest Jun 2026

Mangoceuticals reported a gross margin of 64.31% and a net margin of -2,336.71% for the quarter ended Jun 2026. These financial ratios cover 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
Gross Margin 56.79%61.69%58.98%58.35%68.85%42.77%61.99%76.11%56.78%53.51%60.42%50.31%42.73%64.31%
EBT Margin -2,542.53%-1,617.16%-733.99%-1,050.87%-1,105.87%-1,465.60%-1,499.38%-1,851.45%-4,427.47%-3,221.61%-9,043.49%-2,934.90%-5,014.65%-1,909.52%
EBIT Margin -2,540.78%-1,622.99%-733.99%-1,050.87%-1,105.87%-1,329.13%-1,318.21%-1,594.02%-4,186.75%-3,133.98%-8,953.45%-389.72%-4,606.75%-1,502.45%
EBITDA Margin -2,540.78%-1,622.99%-733.99%-1,050.87%-1,105.87%-1,329.13%-1,318.21%-1,594.02%-4,186.75%-3,133.98%-8,953.45%-389.72%-4,606.75%-1,502.45%
Operating Margin -2,540.78%-1,622.99%-733.99%-1,050.87%-1,105.87%-1,329.13%-1,318.21%-1,594.02%-4,186.75%-3,133.98%-8,953.45%-389.72%-4,606.75%-1,502.45%
Net Margin -2,542.53%-1,617.16%-733.99%-1,050.87%-1,105.87%-1,465.60%-1,719.48%-1,851.22%-4,696.35%-3,396.50%-9,391.80%-3,246.68%-5,447.88%-2,336.71%
FCF Margin -1,798.83%-1,260.71%-697.81%-694.73%-462.94%-966.66%-874.15%-1,073.26%-2,081.11%-747.40%-1,473.38%-1,142.18%-1,932.31%-378.88%
Efficiency
Inventory AverageInventory Avg. 0.02M0.02M0.02M0.01M0.01M-0.00M
Assets AverageAssets Avg. 2.56M3.71M2.45M1.32M0.68M7.77M15.01M15.08M18.56M21.30M18.69M16.31M15.27M14.31M
Invested CapitalInvested Cap. 0.78M0.77M-0.87M14.02M14.02M14.10M20.25M19.74M15.83M12.62M
Asset Utilization RatioAsset Util. 0.551.250.110.050.040.030.020.020.030.030.02
Leverage & Solvency
Interest Coverage RatioInterest Cover 334.04-242.79-99.45-18.70
Debt Ratio 0.170.290.010.010.010.020.010.01
Times Interest Earned 334.04-242.79-99.45-18.70
Valuation
Price to EarningsP/E -5.01-13.39-7.94-1.74-2.16-3.70-3.30-2.46-1.74-2.83-3.19-2.43-1.65-4.26
Price to SalesP/S 127.43216.5858.2518.2623.9354.2956.6645.5081.9496.24299.5878.9890.0399.58
Price to BookP/B 3.3610.1910.545.76-5.350.640.550.340.440.841.600.490.450.55
Enterprise Value 9.04M27.64M13.04M3.71M5.11M8.37M7.46M4.71M8.86M16.06M24.74M5.93M5.92M6.60M
EV to EBIT -3.53-12.06-7.25-1.44-2.16-3.86-4.25-2.81-1.94-3.05-3.28-16.13-1.89-6.39
EV to EBITDA -3.53-12.06-7.25-1.44-2.16-3.86-4.25-2.81-1.94-3.05-3.28-16.13-1.89-6.39
Market Capitalization 12.84M30.59M14.28M4.46M5.12M8.86M7.56M4.79M8.96M16.18M25.24M7.45M6.11M6.85M
Price to FCFP/FCF -7.08-17.18-8.35-2.63-5.17-5.62-6.48-4.24-3.94-12.88-20.33-6.92-4.66-26.28
EV to FCF -4.99-15.52-7.62-2.18-5.15-5.30-6.40-4.17-3.90-12.78-19.93-5.50-4.51-25.33
EV to CFO -5.00-15.52-7.62-2.18-5.15-5.30-6.40-4.17-3.90-12.78-19.93-5.50-4.51-25.33
Return Ratios
Return on Sales [ROS]ROS -2,540.78%-1,622.99%-733.99%-1,050.87%-1,105.87%-1,329.13%-1,318.21%-1,594.02%-4,186.75%-3,133.98%-8,953.45%-389.72%-4,606.75%-1,502.45%
Return on Capital Employed [ROCE]ROCE -828.98%1,683.96%-139.31%-65.05%-58.38%-59.68%-67.42%-106.61%-115.15%-112.21%-93.47%
Return on Assets [ROA]ROA -696.25%-1,333.96%-117.46%-62.12%-57.74%-60.23%-66.69%-106.08%-126.56%-125.79%-105.54%